Allergenic Products Advisory Committee to review AR 101 to treatpeanut allergy

Aimmune Therapeutics, Inc.a biopharmaceutical company developing treatments for life-threatening food allergies, announced that it has been informed by the FDA that the Allergenic Products Advisory Committee (APAC) will review the Biologics License Application (BLA) for AR 101 at its meeting scheduled for 13 September 2019.

Aimmune is developing AR 101, an investigational biologic drug for use in oral immunotherapy, as a treatment to reduce the frequency and severity of adverse events, including anaphylaxis, following exposure to peanuts. Additionally, Aimmune has entered into a commercial supply agreement with CoreRx, Inc., the Company’s long-standing manufacturer of AR 101.